The technology offers a transgenic sugarcane model for production of high value protein molecules e.g., pharmaceutical proteins like vaccines, therapeutic proteins, oral vaccines, or any other intermediate proteins of industrial value.

The transgenic sugarcane model has been developed at Sugarcane Breeding Institute, Coimbatore, India.

**COMPETITIVE ADVANTAGES**

- The yield and activity of the recombinant protein is high.
- The recombinant protein is targeted and stored in vacuole. In a mature cane 80-85% of the cells are filled with vacuole. One kilogram of stalk can give 600-650 ml of juice.
- Sugarcane juice has relatively negligible amount of protein (around 0.04%), hence it would be simpler to purify the heterologous proteins expressed in juice.
- Large storage vacuole makes it possible to store even proteins that are phyto-toxic and thus isolating it from other metabolic pathways.
- Sugarcane being vegetatively propagated, biosafety issues with transgenic sugarcane are low.
- Specific morphologically distinct varieties for different proteins are possible.
- As raw sugarcane juice is palatable direct delivery of vaccines or nutricuticles is possible.

**STATE OF DEVELOPMENT**

The transgenic sugarcane model has been successfully used for the production of Beta-glucuronidase (gus) protein. The yield of partially purified GUS protein is 1mg/ml of juice. The estimated purity is 70%.

**BUSINESS OPPORTUNITY**

BCIL is looking for industrial partners keen to license the transgenic sugarcane model or validate the transgenic model for production of high value protein through option agreement.

CONTACT:
MANAGER (IP AND TECHNOLOGY TRANSFER CELL)
BIOTECH CONSORTIUM INDIA LIMITED
V Floor, Anuvrat Bhawan
210, Deen Dayal Upadhyaya Marg
New Delhi:110 002
Phone: +91-11-23219064-67, 23219053 (Direct) Fax: +91-11-23219063
Email: info.bcil@nic.in Website: www.bcil.nic.in